DISPERSION AND SIZE DISTRIBUTION OF AMILORIDE BY METERED DOSE AND DRY POWDER INHALERS

被引：4

作者：

BOUNDY, MG

LEITH, D

KNOWLES, MR

机构：

[1] Department of Environmental Sciences and Engineering, Chapel Hill

[2] Department of Medicine, University of North Carolina, Chapel Hill

来源：

JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG | 1990年 / 3卷 / 04期

关键词：

D O I：

10.1089/jam.1990.3.233

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

An aerosol of amiloride, nebulized from liquid solution, shows promise as treatment for viscous secretions in the airways of patients with cystic fibrosis. To improve ease of delivery and perhaps pharmacokinetics of amiloride aerosol, we examined two devices that generate dry powder aerosols: (a) the Spinhaler and (b) the metered dose inhaler (MDI). We estimate that treatment will require generation of 8 to 12 mg/day of respirable particles (< 4.7um) to achieve the desired concentrations of drug in the conducting airways. However, oropharyngeal deposition of the drug must be minimized because excessive diuresis or hyperkalemia may develop if the total systemic dose to the patient exceeds 20 mg/day. The Spinhaler was tested alone and in combination with an impactor designed to reduce the mass of large particles deposited in the oropharynx. The MDI was attached to a spacer and studied with and without the same impactor. An Andersen cascade impactor was used to determine the aerodynamic size distribution of the amiloride generated by both devices. The collected amiloride was analyzed by spectrophotometry. We achieved generation of 12 mg/day of respirable amiloride without exceeding a total systemic dose of 20 mg/day using the Spinhaler with the impactor, and by the MDI, spacer, and impactor. Generation of 8 mg/day of respirable amiloride without exceeding a daily systemic dose of 20 mg/day was achieved using the MDI and spacer.

引用

页码：233 / 241

页数：9

共 20 条

[1]

BELL J.H., HARTLEY P.S., COX J.S.G., Dry powder aerosols I: a new powder inhalation device, J. Pharm. Sci., 60, (1971)

[2]

BOUCHER R.C., JAMES M.K., FRIEDMAN M., FULLTON J., PIMMEL R., GATZY J.T., Acute toxicity of intravenous and aerosolized amiloride in the dog, Cystic Fibrosis Club Abstracts, 23rd Annual Meeting, 23, (1982)

[3]

BOUCHER R.C., STUTTS M.J., KNOWLES M.R., CANTLEY L., GATZY J.T., Na+ transport in cystic fibrosis (CF) respiratory epithelia: Abnormal basal rate and response to adenylate cyclase activation, J. Clin. Invest., 78, (1986)

[4]

COX J.S.G., BELL J.H., HARTLEY P.S., Admiinstration of disodium cromoglycate, Brit. Med. J., 2, (1969)

[5]

DOLOVICH M.B., RUFFIN R.E., ROBERTS R.S., NEWHOUSE M.T., Optimal delivery of aerosols from metered dose inhalers, Chest, 80S, (1981)

[6]

HINDS W., Aerosol Technology, (1982)

[7]

KNOWLES M.R., GATZY J.T., BOUCHER R.C., Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis, N. Engl. J. Med., 305, (1981)

[8]

KNOWLES M.R., GATZY J.T., BOUCHER R.C., Relative ion permeability of normal and cystic fibrosis nasal epithelium, J. Clin. Invest., 71, (1983)

[9]

KNOWLES M.R., FULLTON J., JONES D., GATZY J.T., BOUCHER R.C., Effects of oral amiloride in cystic fibrosis and normal subjects, Cystic Fibrosis Club Abstracts, 24th Annual Meeting, 24, (1983)

[10]

KNOWLES M.R., STUTTS M.J., SPOCK A., FISHER N., GATZY J.T., BOUCHER R.C., Abnormal ion permeation through cystic fibrosis respiratory epithelium, Science, 221, (1983)

← 1 2 →